FGEN · FibroGen Inc

-

Please sign in to comment on FGEN

1 Comment

Admin

4 years, 2 months ago

FibroGen, Inc is currently in a long term downtrend where the price is trading 25.9% below its 200 day moving average.

From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 18.2.

FibroGen, Inc's total revenue rose by 715.1% to $65M since the same quarter in the previous year.

Its net income has increased by 40.2% to $-59M since the same quarter in the previous year.

Finally, its free cash flow grew by 79.4% to $-10M since the same quarter in the previous year.

Based on the above factors, FibroGen, Inc gets an overall score of 4/5.

Exchange	NASDAQ
Industry	Biotechnology
CurrencyCode	USD
ISIN	US31572Q8087
Sector	Healthcare

Beta	0.82
PE Ratio	None
Target Price	10
Market Cap	31M
Dividend Yield	None

ABOUT

FibroGen Inc

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

FGEN · FibroGen Inc

-

FibroGen Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest FibroGen Inc using a moving average strategy